Research programme: CDX bi-specific antibodies - Hemogenyx

Drug Profile

Research programme: CDX bi-specific antibodies - Hemogenyx

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hemogenyx
  • Class Bispecific antibodies; Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Stem cell engraftment

Most Recent Events

  • 30 Oct 2017 Hemogenyx enters into a manufacturing agreement with LakePharma
  • 30 Oct 2017 Preclinical trials in Stem cell engraftment in United Kingdom (IV)
  • 30 Oct 2017 Hemogenyx files an IND application with the FDA for Stemcell engraftment before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top